Search This Blog

Monday, April 4, 2022

Ardelyx Announces US Launch of IBSRELA

 

  • IBSRELA®(tenapanor) is the First and Only NHE3 Inhibitor FDA Approved for the Treatment of IBS-C in Adults

  • First Novel Mechanism Therapy to Treat IBS-C in a Decade

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)